美股异动｜Omeros暴涨超156%，获诺和诺德斥资21亿美元购买其实验性罕见疾病药物权利

Core Viewpoint - Omeros Corporation (OMER.US) experienced a significant stock surge of over 156%, reaching $10.51, following the announcement from Novo Nordisk regarding a $2.1 billion investment to acquire rights to an experimental drug for rare diseases [1] Group 1 - Novo Nordisk will pay Omeros an upfront payment of $340 million, along with milestone payments tied to research and commercial achievements [1] - The experimental drug, zaltenibart, is currently undergoing testing for the treatment of rare blood and kidney diseases [1]